Funder: Alzheimer's Association
Due Dates: August 6, 2025 (LOI, 5:00 PM EST) | September 24, 2025 (Full application, invited, 5:00 PM EST)
Funding Amounts: Up to $1,000,000 for Phase 1 studies or up to $2,000,000 for Phase 2 studies over 2–3 years; indirect costs capped at 10% for nonprofits, none for for-profits.
Summary: Supports early-phase clinical trials of innovative gene-targeting therapies for Alzheimer's and related dementias, accelerating translation of genetic discoveries into human studies.
Key Information: LOI required; open to global academic and small for-profit organizations; efficacy cannot be primary outcome.